# A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

> **NCT01379534** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 53 (actual)

## Conditions studied

- Solid Tumors and Advanced Endometrial Cancer
- Endometrial Cancer
- Second-line Treatment
- VEGF

## Interventions

- **DRUG:** TKI258

## Key facts

- **NCT ID:** NCT01379534
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2015-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01379534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01379534, "A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01379534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*